Interactions of DB75, a Novel Antimalarial Agent, with Other Antimalarial Drugs In Vitro | Zendy

Anne Purfield | Zendy; Richard R. Tidwell | Zendy; Steven R. Meshnick | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interactions of DB75, a Novel Antimalarial Agent, with Other Antimalarial Drugs In Vitro

Author(s) -

Anne Purfield,

Richard R. Tidwell,

Steven R. Meshnick

Publication year - 2008

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01536-07

Subject(s) - amodiaquine , mefloquine , artemisinin , pharmacology , chloroquine , atovaquone , antimalarial agent , clindamycin , piperaquine , lumefantrine , artemether , azithromycin , medicine , malaria , plasmodium falciparum , biology , antibiotics , microbiology and biotechnology , immunology

Pafuramidine is a novel orally active antimalarial. To identify a combination partner, we measured the in vitro antimalarial activities of the active metabolite, DB75, with amodiaquine, artemisinin, atovaquone, azithromycin, chloroquine, clindamycin, mefloquine, piperaquine, pyronaridine, tafenoquine, and tetracycline. None of the drugs tested demonstrated antagonistic or synergistic activity in combination with pafuramidine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research